MAPT and Alzheimer disease: Given the importance of tau pathology in AD, as a diagnostic biomarker and a key pathogenic player, this effect of n-3 PUFA, and particularly of EPA on insoluble tau, may provide evidence of a disease-modifying action of these widely available nutraceuticals.